In Goldman's most bullish scenario, assuming Eli Lilly captures 50% of the GLP-1 market, ramps up sufficient supply, and achieves profit margins consistent with blockbuster drugs, Eli Lilly stock could more than double to a market valuation of $1.2 trillion
10.1016/S0092-8674(00)81351-3 Asabe SI, Tanji Y, Satoh S, Kaneko T, Kimura K, Shimotohno K: The N-terminal region of hepatitis C virus-encoded NS5A is important for NS4A-dependent phosphorylation
Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi
Melatonin alleviates doxorubicin-induced mitochondrial oxidative damage and ferroptosis in cardiomyocytes by regulating YAP expression
Melanotan-II is related to, but different from, afamelanotide, an approved drug used to treat the skin condition erythropoietic protoporphyria
A total of 858 annotated and 210 unannotated plasma metabolites were measured